CLOs on the Move

Sanofi Genzyme

www.sanofigenzyme.com

 
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Laura Sorafine
Assistant General Counsel Profile

Similar Companies

Child & Family Services

Child & Family Services is a private, nonprofit, human service agency that provides adoption services, mental health counseling, psychiatry and specialized support programs to people of all ages living in southeastern Massachusetts.

Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with operations in Boston, MA, and Zug, Switzerland.

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Shionogi

Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a 140-year-old global pharmaceutical company with headquarters in Osaka, Japan. In the U.S., Shionogi Inc. leverages our science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in our core areas of infectious diseases and pain, as well as other areas of high medical need, including chronic liver disease.